SHANGHAI – Genhui Chen, CEO and co-founder of Beijing Wenfeng Tianji Pharma Ltd., is at the end of a long road. He is an inventor-entrepreneur waiting patiently for the CFDA to give him the good news he is hoping for: that benvitimod, the first-in-class small-molecule drug he has been developing since the late 1990s, will be approved for mild to moderate psoriasis in China.